Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity

Purpose: The use of the CD20-specific antibody rituximab has greatly improved the response to treatment of CD20+ follicular lymphoma. Despite the success of rituximab, resistance has been reported and prognostic markers to predict individual response are lacking. The level of CD20 expression on tumors has been related to response, but results of several studies are contradictory and no clear relationship could be established. Complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) are thought to be important effector mechanisms, but the exact mechanism of rituximab-mediated cell kill is still unknown. Importantly, no data have been reported on the combined contribution of CDC and ADCC. Experimental Design: We have developed a system of clonally related CEM-CD20 cells by retroviral transfer of the human CD20 cDNA (n = 90). This set of cells, with the CD20 molecule as the only variable, was used to study the importance of CD20 expression level on rituximab-mediated CDC, ADCC, and the combination. Results: We show a sigmoidal correlation of CD20 expression level and rituximab-mediated killing via CDC but not ADCC. On both high and low CD20-expressing cells, all CD20 molecules were translocated into lipid rafts after rituximab binding. Furthermore, CDC and ADCC act simultaneously and CDC-resistant cells are sensitive to ADCC and vice versa. Conclusions: These findings suggest that CDC depends on CD20 expression level and that both CDC and ADCC act complementary. These data give new insights into novel strategies to improve the efficacy of CD20-specific antibodies for the treatment of CD20+ tumors.

[1]  A. López-Guillermo,et al.  Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. , 2001, Blood.

[2]  A. Kennedy,et al.  An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. , 2003, Blood.

[3]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[4]  C. Perry,et al.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. , 2006, Drugs.

[5]  Huifen Li,et al.  Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms , 2005, The Journal of Immunology.

[6]  A. Krieg,et al.  From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. , 2001, Antisense & nucleic acid drug development.

[7]  A. Hagenbeek,et al.  UTY‐specific TCR‐transfer generates potential graft‐versus‐leukaemia effector T cells , 2005, British journal of haematology.

[8]  J. Baars,et al.  Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.

[9]  U. Jäger,et al.  Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies? , 2002, Journal of Clinical Immunology.

[10]  J. Emtage,et al.  The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. , 1995, Immunology.

[11]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[12]  D. Maloney,et al.  IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma , 1997 .

[13]  I. Stamenkovic,et al.  Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein , 1988, The Journal of experimental medicine.

[14]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Weng,et al.  Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. , 2001, Blood.

[16]  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer immunology, immunotherapy : CII.

[17]  I. Sanz,et al.  The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus , 2003 .

[18]  J. Friedberg.  Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. , 2005, Hematology. American Society of Hematology. Education Program.

[19]  Hervé Watier,et al.  From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.

[20]  G. Häcker,et al.  Activation of the immune system by bacterial CpG‐DNA , 2002, Immunology.

[21]  A. Difrancesco,et al.  Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[22]  A. Hagenbeek,et al.  The CD20/αCD20 ‘suicide’ system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells , 2006, Gene Therapy.

[23]  T. Sauerbruch,et al.  Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines. , 1999, Hybridoma.

[24]  I. Sanz,et al.  B cells as therapeutic targets for rheumatic diseases , 2004, Current opinion in rheumatology.

[25]  L. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for Fc g RI, Fc g RII, Fc g RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc g R* , 2001 .

[26]  P. Venugopal,et al.  Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. , 2000, Leukemia research.

[27]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[28]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[29]  J. Ledbetter,et al.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. , 1998, Blood.

[30]  T N Schumacher,et al.  Changing T cell specificity by retroviral T cell receptor display. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Polyak,et al.  CD20‐mediated apoptosis: signalling through lipid rafts , 2002, Immunology.

[32]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[33]  Leonard G. Presta,et al.  Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc , 2000, The Journal of Immunology.

[34]  M. Frank,et al.  The role of complement in inflammation and phagocytosis. , 1991, Immunology today.

[35]  Robert Huber,et al.  The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex , 2000, Nature.

[36]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[37]  C. Harding,et al.  CpG DNA Induces Maturation of Dendritic Cells with Distinct Effects on Nascent and Recycling MHC-II Antigen-Processing Mechanisms , 2000, The Journal of Immunology.

[38]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[39]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[40]  D. R. Anderson,et al.  Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. , 1997, Biochemical Society transactions.

[41]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[42]  E. Everett,et al.  Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia , 1992, American journal of hematology.

[43]  R. Gressin,et al.  In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. , 2003, Blood.

[44]  D. Maloney,et al.  Rituximab: mechanism of action and resistance. , 2002, Seminars in oncology.

[45]  A. Mantovani,et al.  Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. , 2002, Blood.

[46]  J. Falkenburg,et al.  New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. , 2004, Blood.

[47]  T. Barbui,et al.  CD 20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia : further regulation by CD 55 and CD 59 , 2001 .

[48]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[49]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Ho,et al.  Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.

[51]  M. Pepys,et al.  Activation of mouse complement by different classes of mouse antibody. , 1979, Immunology.

[52]  H. Kantarjian,et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  L. Presta,et al.  FcRn and Design of IgG 1 Variants with Improved Binding to the Fc g R * , 2001 .

[54]  P. Colombat,et al.  Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.

[55]  T. Barbui,et al.  Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. , 2000, Human gene therapy.

[56]  M. Cragg,et al.  Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. , 2003, Blood.